Komori
Medikit (7749) · PolicyAdvancedLatest Share Issuance and Disposal (2026-07-24): "Achieved"

Policy for Determining Executive Compensation Based Primarily on Fixed Compensation

First written in FY2021. 5 of 9 entries say "Advanced", first in FY2023-Q2. Latest entry: 2026-07-24.

9entries
6years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021AdvancedFY2023-Q2 – FY2025-H1RestatedFY20252021: 120212022: 220222023: 120232024: 120242025: 120252026: 32026
Same theme, other companies
Executive Compensation Policy and Design Combining Fixed and Share-Based CompensationA theme 100 companies write about · 14 as a headwind · 62 as a tailwind

The whole theme swung hardest in 2024: 8 of 49 companies on the "Worse" side.

8 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 100 companies compared. The sentences above are computed from all 100.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Other during the fiscal year consisted of the disposal of treasury shares as restricted stock compensation carried out on 25 July 2025.」

    The Company disposed of 12,500 shares as restricted stock compensation and continued operating the system combining fixed compensation and restricted stock compensation.
  2. FY2025RestatedAnnual report

    「The types of remuneration are monthly fixed cash compensation and restricted stock compensation paid as non-monetary compensation. However, outside directors and Audit & Supervisory Board Members receive only fixed monthly cash compensation.」

    The Company continues to operate a system based primarily on fixed compensation that provides restricted stock compensation to directors other than outside directors and others. Restricted stock compensation of ¥23.430 million was recorded for the fiscal year.
  3. FY2025-H1AdvancedAnnual report

    「Pursuant to a resolution of the Board of Directors dated 26 June 2024, the Company disposed of 13,800 treasury shares on 25 July 2024 as restricted stock compensation.」

    The Company disposed of 13,800 treasury shares on 25 July 2024 as restricted stock compensation.
  4. FY2024-Q2AdvancedAnnual report

    「(Note) Pursuant to a resolution of the Board of Directors dated 28 June 2023, 8,700 treasury shares were disposed of on 27 July 2023 as restricted stock compensation.」

    The Company disposed of 8,700 treasury shares on 27 July 2023 under the restricted stock compensation plan introduced in FY2022.
  5. FY2023-Q2AdvancedAnnual report

    「(Note) Pursuant to a resolution of the Board of Directors dated 29 June 2022, the Company disposed of 8,400 treasury shares on 28 July 2022 as restricted stock compensation.」

    The Company disposed of 8,400 treasury shares under the restricted stock compensation plan whose introduction was approved in FY2022.
  6. FY2022ReframedAnnual report

    「At the 39th Annual General Meeting of Shareholders held on 29 June 2022, the Company resolved to introduce a restricted stock compensation plan, and the types of remuneration are monthly fixed cash compensation and restricted stock compensation paid as non-monetary compensation.」

    The policy was changed from one providing only fixed monthly compensation to one adding restricted stock compensation for directors other than outside directors and others. The introduction of the plan was disclosed as a subsequent event based on a shareholders’ meeting resolution made before the submission date.
  7. FY2021First statedAnnual report

    「Compensation consists of monthly fixed cash compensation, and the company does not provide performance-linked compensation or non-monetary compensation.」

    Regarding remuneration for directors and Audit & Supervisory Board Members, the Company has disclosed for the first time, in an organized form, its policy of basing remuneration on fixed monthly compensation and not adopting performance-linked or non-monetary compensation.
Moved together

"Retained Earnings for Stable Dividends, Development and Investment" moved the same way as this thread, in the same document, in 2 of its 9 moves.

222222★123456
  1. ★This thread
  2. 1Retained Earnings for Stable Dividends, Development and Investment2×
  3. 2Strengthening the endovascular treatment of cerebrovascular disease business through the conversion of Bolt Medical Co., Ltd. into a wholly owned subsidiary2×
  4. 3Launch and Improvement of Products with Safety Mechanisms and New Catheter Products2×
  5. 4Enhancement of Component Production Capacity at the Hyuga Plant and Hyuga No. 2 Plant2×
  6. 5Sales dependence on products related to hemodialysis2×
  7. 6Holding of 962,200 treasury shares2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medikit's next results are scheduled for 2026-11-12. Read the earnings preview It last moved in the Share Issuance and Disposal of 2026-07-24: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Policy for Determining Executive Compensation Based Primarily on Fixed Compensation | MEDIKIT CO.,LTD. (7749) | Komori